Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jazz Pharmaceuticals, Inc. on March 25, 2011. The report addresses corporate governance changes regarding the Board of Directors ahead of the 2011 Annual Meeting of Stockholders, expected to be held in late May 2011.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters.
Material Changes
- Director Departures: Nathaniel Zilkha and James Tananbaum, MD, notified the Company on March 25, 2011, of their intent not to stand for re-election to the Board of Directors.
- Term End Dates: The terms of office for both Mr. Zilkha and Dr. Tananbaum will conclude on the date of the Annual Meeting.
- Board Size Reduction: The Board intends to decrease the total number of authorized directors from twelve (12) to ten (10), effective on the date of the Annual Meeting.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirm the exact date of the 2011 Annual Meeting of Stockholders.
- Verify the names and qualifications of the nominees proposed to fill the vacancies left by Mr. Zilkha and Dr. Tananbaum.
- Review the proxy statement for details on the rationale for reducing the Board size from 12 to 10 members.